OS Therapies Initiates FDA BLA Filing for OST-HER2 to Prevent or Delay Recurrent Pulmonary Metastatic Osteosarcoma

Regenerative Medicine Advanced Therapy (RMAT) designation requests update submitted to FDA with recent biomarker data ...

Revolution Medicines Conference: CEO Details Daraxonrasib Phase III Timeline, First-Line PDAC Push

CEO Mark Goldsmith outlined the company’s late-stage plans for its RAS(ON) inhibitor daraxonrasib, discussed expansion into first-line pancreatic cancer, and offered updates on colorectal cancer and e ...

Former Microsoft Quantum Program Manager Joins Haiqu to Lead Product Launch

Dr. Antonio Mei brings 10+ years experience in HPC, AI and quantum computing I look forward to leading the development ...
How-To Geek on MSN

How I built the perfect programming platform in under 10 minutes

Building your perfect programming environment is easier than you think. Here's how to do it in minutes!